Merck, Inc.
🇵🇭Philippines
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2015-02-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT00035282
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
Phase 1
Completed
- Conditions
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 132
- Registration Number
- NCT00034684
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00034632
Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT00034645
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00034697
Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 336
- Registration Number
- NCT00034658
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 98
- Registration Number
- NCT00034671
A Study in Adult and Pediatric Patients With Cystic Fibrosis
Phase 1
Completed
- Conditions
- First Posted Date
- 2002-04-30
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT00034515
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
Phase 4
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00002376
- Locations
- 🇺🇸
Kaiser Foundation Hospital, San Francisco, California, United States
Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole
Phase 2
Terminated
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 70
- Registration Number
- NCT00005920
- Locations
- 🇺🇸
Carol Sable, Rahway, New Jersey, United States
© Copyright 2024. All Rights Reserved by MedPath